Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA
Abstract
Aim: To describe treatment patterns and outcomes of patients with unresectable stage III and metastatic/stage IV melanoma. Materials & methods: An observational retrospective chart review of patients diagnosed with advanced melanoma before 1 November 2015 who initiated a new line of therapy (LOT) from 1 January 2015 to 31 May 2016. Results: Among 487 patients, ipilimumab monotherapy (27.5%) was the most common first line of therapy (1LOT) in 2015, surpassed by nivolumab monotherapy (21.5%) in 2016. 12-month survival was ≥80.1%; proportions were highest forpatients treated with nivolumab + ipilimumab (86.6%). All treatments relatively well tolerated in real-world setting and adverse events were consistent with the previously reported safety profiles. Conclusion: This study provides important insights into real-world advanced melanoma treatment patterns and demonstrates encouraging treatment safety and patient survival data.
Supplementary Material
File (supplementary_figures.docx)
- Download
- 76.21 KB
References
Papers of special note have been highlighted as: • of interest
1.
National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: melanoma of the skin (2018). https://seer.cancer.gov/statfacts/html/melan.html.
2.
Bristol-Myers Squibb. Yervoy (ipilimumab) package insert (2011). https://packageinserts.bms.com/pi/pi_yervoy.pdf.
3.
Genentech. Zelboraf (vemurafinib) package insert (2011). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdf.
4.
Novartis. Tafinlar (dabrafenib) package insert (2013). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf.
5.
Novartis. Mekinist (trametinib) package insert (2013). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf.
6.
Merck. Keytruda (pembrolizumab) package insert (2014). https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
7.
Squib BM. Opdivo (Nivolumab) package insert (2014). https://packageinserts.bms.com/pi/pi_opdivo.pdf.
8.
Genentech. Cotellic (cobimetinib) package insert (2015). https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf.
9.
Sharma SP. A new standard of care for metastatic melanoma? Lancet Oncol. 16(1), e8 (2015).
10.
Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
• Demonstrates a clear survival benefit for combination therapy, while maintaining an acceptable tolerability profile.
11.
Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694–1703 (2012).
12.
Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371(20), 1877–1888 (2014).
13.
Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, Phase III randomised controlled trial. Lancet 386(9992), 444–451 (2015).
14.
Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372(1), 30–39 (2015).
15.
Long GV, Eroglu Z, Infante JR et al. Five-year overall survival (OS) update from a Phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). J. Clin. Oncol. 35(15 Suppl.), 9505 (2017).
16.
Middleton MR, Dalle S, Claveau J et al. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Med. 5(7), 1436–1443 (2016).
17.
Uprety D, Bista A, Chennamadhavuni A et al. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study. Melanoma Res. 28(1), 56–60 (2018).
• Compares overall survival between in the time frame before targeted therapies where available and immediately afterwards, demonstrating a clear survival benefit in the era of targeted therapies. It is limited by the few number of targeted and immunotherapies included.
18.
Cowey CL, Liu FX, Black-Shinn J et al. Pembrolizumab utilization and outcomes for advanced melanoma in US community oncology practices. J. Immunother. 41(2), 86–95 (2018).
• Demonstrates longer overall survival times in a real world setting, with results similar to our study.
19.
Coit DG, Thompson JA, Algazi A et al. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 14(4), 450–473 (2016).
20.
National Comprehensive Cancer Network. NCCN Guidelines – melanoma. NCCN Guidelines Version 2.2018 (2018).
21.
Ma Q, Chen YJ, Hines DM et al. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. J. Dermatolog. Treat. 28(6), 549–553 (2017).
• Represents one of the few analysis of real world data in patients with metastatic melanoma. The main findings on duration of treatment were similar to our findings. Its main limitation is that the observation window occurs prior to the availability of most immunotherapies studies in our research with the exception of ipilimumab monotherapy.
22.
Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr. Med. Res. Opin. 31(8), 1561–1572 (2015).
23.
Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
24.
Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006–2017 (2015).
25.
Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320–330 (2015).
26.
Robert C, Schachter J, Long GV et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521–2532 (2015).
27.
Barone A, Hazarika M, Theoret MR et al. FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin. Cancer Res. 23(19), 5661–5665 (2017).
28.
Hodi FS, Chesney J, Pavlick AC et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, Phase II trial. Lancet Oncol. 17(11), 1558–1568 (2016).
29.
Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, Phase II trial. Lancet Oncol. 16(8), 908–918 (2015).
30.
Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase III trial. Lancet Oncol. 16(4), 375–384 (2015).
Information & Authors
Information
Published In
Copyright
© 2019 Future Medicine Ltd.
History
Received: 3 January 2019
Accepted: 13 February 2019
Published online: 5 March 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0003
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Dweeti Nayak, Katherine G. Akers, Andrew M. Frederickson, Yves P.V. Mbous, Raquel Aguiar-Ibáñez, Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy, Frontiers in Oncology, 10.3389/fonc.2025.1615795, 15, (2025).
- Namrata Bhadouria, Aftab Alam, Awaneet Kaur, Unraveling Skin Carcinoma: A Comprehensive Examination of Diagnosis, Treatment Strategies, and Emerging Therapeutic Avenues in Skin Cancer Management, Pharmaceutical Nanotechnology, 10.2174/0122117385282163240220072251, 13, 4, (648-664), (2025).
- John P. Garcia, Olivia A. Ho, Syed Ali Haider, Sahar Borna, Cesar A. Gomez-Cabello, Antonio Jorge Forte, Aaron C. Spaulding, Impact of Physician Specialty on Treatment Costs of Invasive Melanoma, Diseases, 10.3390/diseases12110284, 12, 11, (284), (2024).
- Ahmet Bozkurt, Aycan Sengul, Comparison of photon interaction coefficients for tumor compositions and healthy tissues simulated by Monte Carlo, Journal of Instrumentation, 10.1088/1748-0221/19/07/P07035, 19, 07, (P07035), (2024).
- Kalpana Mangal, Alankrita Madhur, Ishita Bansal, Sinonasal malignant melanoma- Diagnostically hidden Gem, IP Archives of Cytology and Histopathology Research, 10.18231/j.achr.2023.067, 8, 4, (292-295), (2024).
- Brian Ko, Kevin Tao, Lachlan Brennan, Swanand Rakhade, Cynthia X. Chan, Jee-Young Moone, Richard Zhu, Ariel Sher, Samuel Wang, Yadriel Bracero, Ben Fullerton, Beth McLellan, Larisa J. Geskin, Yvonne M. Saenger, Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients, Melanoma Research, 10.1097/CMR.0000000000000945, 34, 2, (134-141), (2024).
- Dimitrios Bafaloukos, Panagiotis Kouzis, Panagiotis Gouveris, Ioannis Boukovinas, Konstantinos Kalbakis, Sofia Baka, Georgios Kyriakakis, Despoina Moschou, Aristea Molfeta, Stamatia Demiri, Dimitrios Mavroudis, Filio Spanoudi, Ioannis Dimitriadis, Helen Gogas, Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015–2018 in Greece. The ‘SUMMER’ study: a retrospective multicenter chart review project, Melanoma Research, 10.1097/CMR.0000000000000949, 34, 2, (152-165), (2023).
- You Sung Nam, Martin J. Bullock, David Forner, Matthew H. Rigby, Martin Corsten, Jonathan R.B. Trites, S. Mark Taylor, A case report: Primary malignant melanoma of the glottic larynx – A very rare entity, Otolaryngology Case Reports, 10.1016/j.xocr.2023.100542, 28, (100542), (2023).
- Milica Markelić, Marija Mojić, Dijana Bovan, Sanja Jelača, Zorana Jović, Milica Purić, Djuro Koruga, Sanja Mijatović, Danijela Maksimović-Ivanić, Melanoma Cell Reprogramming and Awakening of Antitumor Immunity as a Fingerprint of Hyper-Harmonized Hydroxylated Fullerene Water Complex (3HFWC) and Hyperpolarized Light Application In Vivo, Nanomaterials, 10.3390/nano13030372, 13, 3, (372), (2023).
- Iyad Kobeissi, Ahmad A. Tarhini, Systemic adjuvant therapy for high-risk cutaneous melanoma, Therapeutic Advances in Medical Oncology, 10.1177/17588359221134087, 14, (2022).